PMID- 29108907
OWN - NLM
STAT- MEDLINE
DCOM- 20181012
LR  - 20231129
IS  - 1097-6787 (Electronic)
IS  - 0190-9622 (Linking)
VI  - 78
IP  - 3
DP  - 2018 Mar
TI  - Subclinical sensitization with diphenylcyclopropenone is sufficient for the 
      treatment of alopecia areata: Retrospective analysis of 159 cases.
PG  - 515-521.e4
LID - S0190-9622(17)32600-2 [pii]
LID - 10.1016/j.jaad.2017.10.042 [doi]
AB  - BACKGROUND: Contact immunotherapy with diphenylcyclopropenone (DPCP) is presently 
      considered the treatment of choice for extensive alopecia areata. However, a 
      major concern with contact immunotherapy is that it causes various adverse 
      effects (AEs) that contribute to discontinuation of treatment. OBJECTIVE: We 
      investigated whether a modified DPCP treatment protocol can promote hair regrowth 
      with fewer AEs. METHODS: All patients were sensitized with 0.1% DPCP and began 
      treatment with 0.01% DPCP. Thereafter, the DPCP concentration was slowly 
      increased according to the treatment response and AEs. This was a retrospective 
      review of DPCP treatment with modified protocols in 159 patients with alopecia 
      areata. RESULTS: Of the 159 patients, 46 (28.9%) showed a complete response and 
      59 (37.1%) showed a partial response. No patients had AEs after sensitization. 
      During the treatment, only 3 patients (1.9%) showed severe AEs, and 55 showed 
      moderate AEs; however, all were well controlled with antihistamines alone or 
      antihistamines and medium-potency topical steroids. There was no association 
      between treatment response and AEs. LIMITATIONS: Sample size, subject 
      composition, and the retrospective study design represent potential limitations. 
      CONCLUSION: A modified DPCP treatment protocol with subclinical sensitization 
      could induce a favorable therapeutic response and result in fewer AEs.
CI  - Copyright (c) 2017 American Academy of Dermatology, Inc. Published by Elsevier Inc. 
      All rights reserved.
FAU - Choe, Sung Jay
AU  - Choe SJ
AD  - Department of Dermatology and Institute of Hair and Cosmetic Medicine, Yonsei 
      University Wonju College of Medicine, Wonju, Republic of Korea.
FAU - Lee, Solam
AU  - Lee S
AD  - Department of Dermatology and Institute of Hair and Cosmetic Medicine, Yonsei 
      University Wonju College of Medicine, Wonju, Republic of Korea.
FAU - Pi, Long Quan
AU  - Pi LQ
AD  - Department of Dermatology and Institute of Hair and Cosmetic Medicine, Yonsei 
      University Wonju College of Medicine, Wonju, Republic of Korea.
FAU - Keum, Dong In
AU  - Keum DI
AD  - Department of Dermatology and Institute of Hair and Cosmetic Medicine, Yonsei 
      University Wonju College of Medicine, Wonju, Republic of Korea.
FAU - Lee, Chung Hyeok
AU  - Lee CH
AD  - Department of Dermatology and Institute of Hair and Cosmetic Medicine, Yonsei 
      University Wonju College of Medicine, Wonju, Republic of Korea.
FAU - Kim, Beom Jun
AU  - Kim BJ
AD  - Department of Dermatology and Institute of Hair and Cosmetic Medicine, Yonsei 
      University Wonju College of Medicine, Wonju, Republic of Korea.
FAU - Lee, Won-Soo
AU  - Lee WS
AD  - Department of Dermatology and Institute of Hair and Cosmetic Medicine, Yonsei 
      University Wonju College of Medicine, Wonju, Republic of Korea. Electronic 
      address: leewonsoo@yonsei.ac.kr.
LA  - eng
PT  - Journal Article
DEP - 20171103
PL  - United States
TA  - J Am Acad Dermatol
JT  - Journal of the American Academy of Dermatology
JID - 7907132
RN  - 0 (Cyclopropanes)
RN  - 0 (Dermatologic Agents)
RN  - I7G14NW5EC (diphenylcyclopropenone)
SB  - IM
CIN - J Am Acad Dermatol. 2023 Dec;89(6):1237. PMID: 37595890
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Alopecia Areata/*therapy
MH  - Cyclopropanes/*administration & dosage/adverse effects
MH  - Dermatologic Agents/*administration & dosage/adverse effects
MH  - Female
MH  - Hair/growth & development
MH  - Humans
MH  - Immunotherapy/adverse effects/*methods
MH  - Male
MH  - Middle Aged
MH  - Recurrence
MH  - Retrospective Studies
MH  - Risk Factors
MH  - Treatment Outcome
MH  - Young Adult
OTO - NOTNLM
OT  - DPCP
OT  - adverse effect
OT  - alopecia areata
OT  - diphenylcyclopropenone
OT  - immunotherapy
OT  - sensitization
EDAT- 2017/11/08 06:00
MHDA- 2018/10/13 06:00
CRDT- 2017/11/08 06:00
PHST- 2017/08/29 00:00 [received]
PHST- 2017/10/24 00:00 [revised]
PHST- 2017/10/29 00:00 [accepted]
PHST- 2017/11/08 06:00 [pubmed]
PHST- 2018/10/13 06:00 [medline]
PHST- 2017/11/08 06:00 [entrez]
AID - S0190-9622(17)32600-2 [pii]
AID - 10.1016/j.jaad.2017.10.042 [doi]
PST - ppublish
SO  - J Am Acad Dermatol. 2018 Mar;78(3):515-521.e4. doi: 10.1016/j.jaad.2017.10.042. 
      Epub 2017 Nov 3.